Patrick Bhola

Patrick Bhola is an Instructor at Dana-Farber Cancer Institute (DFCI) and Co-Director of the Letai Lab at Harvard Medical School. He holds a BASc from the University of Toronto and a PhD from Rockefeller University, having joined the Letai Lab in 2010. His academic appointment is within the Department of Cancer Biology at Harvard Medical School.

Dr. Bhola's research focuses on apoptotic heterogeneity within tumors, with particular emphasis on developing high-throughput approaches to evaluate chemicals that sensitize tumors for apoptosis. His work bridges basic molecular mechanisms of cell death with translational applications in precision oncology. He has made significant contributions to understanding how tumor cells evade apoptosis and how this knowledge can be leveraged to develop more effective cancer treatments.

Analysis of Dr. Bhola's publication record reveals a consistent focus on apoptosis mechanisms in cancer, with increasing emphasis on precision oncology approaches. His work spans from fundamental mitochondrial biology to clinical applications of BH3 mimetics across multiple cancer types including leukemia, breast cancer, and sarcomas. Recent publications demonstrate a growing interest in single-cell analysis of apoptotic responses and metabolic determinants of treatment sensitivity.

Dr. Bhola serves as Co-Director of the Letai Lab, which is renowned for its work on BH3 profiling and the development of BH3 mimetics as cancer therapeutics. The lab maintains active collaborations across multiple institutions and has received significant funding for its innovative approaches to understanding and overcoming treatment resistance in cancer.